Skip to main content

Advertisement

SpringerLink
Log in

Impact of chemotherapy beyond the first line in patients with metastatic breast cancer

  • Clinical Trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose

The goal of this study was to determine which benefit could be brought by the succession of chemotherapy lines in patients treated for metastatic breast cancer and to identify patients who benefit from these treatments.

Patients and methods

Nine hundred and thirty four patients with metastatic breast cancer diagnosed between 1992 and 2002 were studied. A total of 772, 505, 283, 127 and 55 patients received a first, second, third, fourth and fifth line of chemotherapy, respectively. The evaluation of benefit in each chemotherapy lines was based on time of disease control (TDC). TDC is defined as time between the date of the beginning of treatment and the date of progression of disease or death. In case of early progressive disease or progression diagnosed at the first evaluation, TDC value is zero. Cox proportional hazards model was used to identify factors that could influence the TDC in each line of chemotherapy.

Results

Medians duration of TDC are 9.3 [0–120], 5.9 [0–83.6], 4.63 [0–37.2], 4.1 [0–36.7] and 0.23 months [0–15] in first, second, third, fourth and fifth lines, respectively. More interestingly, TDC was longer than 6 months in 50.5% of patients treated with second line, 40% with third line, 35% with fourth line and 23.5% with fifth line. These results justify the therapeutic succession of chemotherapy lines in metastatic breast cancer. Only one factor influences the duration of TDC for each line of treatment: duration of TDC observed in the previous line.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94(2):153–156

    Article  PubMed  CAS  Google Scholar 

  2. Dickson R, Pestell R, Lippman M (2005) Metastatic breast cancer. In: DeVita T, Hellman S, Rosenberg S (eds) Cancer principles and practice of oncology, 7 edn. Lippincot company, Philadelphia, pp 1453–1462

    Google Scholar 

  3. Ellis M, Hayes D, Lippman M (2000) Treatment of metastatic breast cancer. In: Harris J, Lippman M, Morrow M, Osborne C (eds) Diseases of the breast, 2 edn. Lippincot company, Philadelphia, pp 749–797

    Google Scholar 

  4. Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100(1):44–52

    Article  PubMed  Google Scholar 

  5. Fossati R, Confalonieri C, Torri V et al (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16(10):3439–3460

    PubMed  CAS  Google Scholar 

  6. A’Hern RP, Smith IE, Ebbs SR (1993) Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67(4):801–805

    PubMed  CAS  Google Scholar 

  7. Andre F, Slimane K, Bachelot T et al (2004) Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 22(16):3302–3308

    Article  PubMed  Google Scholar 

  8. Jassem J, Pienkowski T, Pluzanska A et al (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19(6):1707–1715

    PubMed  CAS  Google Scholar 

  9. Alba E, Martin M, Ramos M et al (2004) Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 22(13):2587–2593

    Article  PubMed  CAS  Google Scholar 

  10. Biganzoli L, Cufer T, Bruning P et al (2002) Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 20(14):3114–3121

    Article  PubMed  CAS  Google Scholar 

  11. Sledge GW, Neuberg D, Bernardo P et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21(4):588–592

    Article  PubMed  Google Scholar 

  12. Nabholtz JM, Falkson C, Campos D et al (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21(6):968–975

    Article  PubMed  CAS  Google Scholar 

  13. Ejlertsen B, Mouridsen HT, Langkjer ST et al (2004) Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol 22(12):2313–2320

    Article  PubMed  CAS  Google Scholar 

  14. Nabholtz JM, Senn HJ, Bezwoda WR et al (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17(5):1413–1424

    PubMed  CAS  Google Scholar 

  15. Sjostrom J, Blomqvist C, Mouridsen H et al (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 35(8):1194–1201

    Article  PubMed  CAS  Google Scholar 

  16. O’Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20(12):2812–2823

    Article  PubMed  CAS  Google Scholar 

  17. Greenberg PA, Hortobagyi GN, Smith TL et al (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14(8):2197–2205

    PubMed  CAS  Google Scholar 

  18. Pivot X, Asmar L, Buzdar AU et al (2000) A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 82(3):529–534

    Article  PubMed  CAS  Google Scholar 

  19. Cardoso F, Di LA, Lohrisch C et al (2002) Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 13(2):197–207

    Article  PubMed  CAS  Google Scholar 

  20. Ramirez AJ, Towlson KE, Leaning MS et al (1998) Do patients with advanced breast cancer benefit from chemotherapy? Br J Cancer 78(11):1488–1494

    PubMed  CAS  Google Scholar 

  21. Modi S, Panageas KS, Duck ET et al (2002) Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer. J Clin Oncol 20(17):3665–3673

    Article  PubMed  CAS  Google Scholar 

  22. Geels P, Eisenhauer E, Bezjak A et al (2000) Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18(12):2395–2405

    PubMed  CAS  Google Scholar 

  23. Coates AS, Hurny C, Peterson HF et al (2000) Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. J Clin Oncol 18(22):3768–3774

    PubMed  CAS  Google Scholar 

  24. Efficace F, Biganzoli L, Piccart M et al (2004) Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 40(7):1021–1030

    Article  PubMed  CAS  Google Scholar 

  25. Coates A, Gebski V, Bishop JF et al (1987) Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 317(24):1490–1495

    Article  PubMed  CAS  Google Scholar 

  26. Rizzieri DA, Vredenburgh JJ, Jones R et al (1999) Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol 17(10):3064–3074

    PubMed  CAS  Google Scholar 

  27. Nisman B, Barak V, Hubert A et al (2003) Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel chemotherapy. Anticancer Res 23(2C):1939–1942

    PubMed  Google Scholar 

  28. Nomura Y (1998) Different survival determinants of metastatic breast cancer patients treated with endocrine therapy or chemo-endocrine therapy. Int J Oncol 12(4):817–824

    PubMed  CAS  Google Scholar 

  29. Falkson G, Holcroft C, Gelman RS et al (1995) Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 13(6):1453–1458

    PubMed  CAS  Google Scholar 

  30. Yamamoto N, Watanabe T, Katsumata N et al (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 16(7):2401–2408

    PubMed  CAS  Google Scholar 

  31. Alexandre J, Bleuzen P, Bonneterre J et al (2000) Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 18(3):562–573

    PubMed  CAS  Google Scholar 

  32. Hortobagyi GN, Smith TL, Legha SS et al (1983) Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1(12):776–786

    PubMed  CAS  Google Scholar 

  33. McQuellon RP, Muss HB, Hoffman SL et al (1995) Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol 13(4):858–868

    PubMed  CAS  Google Scholar 

  34. Bremnes RM, Andersen K, Wist EA (1995) Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy. Eur J Cancer 31A(12):1955–1959

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical oncology, CHU Minjoz, Bd Fleming, Besancon, 25 030, France

    Armelle Dufresne, Xavier Pivot, Christophe Tournigand, Thomas Facchini, Thierry Altweegg, Loic Chaigneau & Aimery De Gramont

Authors
  1. Armelle Dufresne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xavier Pivot
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christophe Tournigand
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Thomas Facchini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thierry Altweegg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Loic Chaigneau
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Aimery De Gramont
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xavier Pivot.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dufresne, A., Pivot, X., Tournigand, C. et al. Impact of chemotherapy beyond the first line in patients with metastatic breast cancer. Breast Cancer Res Treat 107, 275–279 (2008). https://doi.org/10.1007/s10549-007-9550-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-007-9550-7

Keywords

Search

Navigation